Method for determining deletions in HBV pre-s2 region

Abstract

A method of detecting pre-S2 deletion mutant LHBS is disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a divisional of U.S. patent application Ser. No. 14 / 333,346, filed on Jul. 16, 2014, in the United States Patent and Trademark Office, which claims the benefit of U.S. Provisional Application No. 61 / 846,764, filed on Jul. 16, 2013, the disclosure of which is incorporated herein in their entirety by reference.BACKGROUND OF THE INVENTION1. Field of the Invention[0002]The present invention generally relates to a method of detecting pre-S2 deletion mutant large hepatitis B virus surface protein.2. Description of the Related Art[0003]Chronic hepatitis B virus infection is a major cause of hepatocellular carcinoma (HCC) worldwide and its most important cause in Asia. Hepatitis B virus (HBV)-related HCC often occurs at the age of 40 or older, suggesting that HBV may persist in carriers for decades before HCC actually develops. It is important for long-term monitoring high-risk markers in chronic HBV carriers to identify the on...

AI Technical Summary

Benefits of technology

The immunoassay kit enables rapid and accurate detection of pre-S2 deletion mutant LHBS, reducing the complexity of previous methods and providing a reliable marker for assessing HCC risk in HBV carriers and recurrence in HCC patients post-surgery.

Problems solved by technology

Though up to now the methods (e.g. ultrasound) and tumor markers (e.g. alpha-fetal protein) to diagnose HCC have been established, the high-risk markers for HCC incidence and recurrence have not been fully identified, given that HCC tumorigenesis is a complex process regulated by various crosstalks between host and viral factors.

It was found that the WT and pre-S mutant LHBS often co-exist in one individual HBV carrier, which makes the detection of the pre-S mutant difficult.

Moreover, it requires labor-intensive process for cloning and isolating each individual gene product before the chip analysis.

Images